| abstract |
IT REFERS TO THE USE OF PYRROLIDINE AND PIPERIDINE DERIVATIVES OF FORMULAS I AND II; R1 AND R2 ARE H, ALCOXYL, HYDROXYL, HALOGEN, AMONG OTHERS; R3 AND R4 ARE H, ALCOXYL, BENZYLOXYL, HALOGEN, AMONG OTHERS; R5 IS H, ALKYL; X AND Y ARE -CH (OH) -, - (CH2) n, -C (O) -, -CH (ALCOXYL) -; m, n AND p ARE 1 or 2. PREFERRED COMPOUNDS ARE 4 - [(RS) -HYDROXY - [(2SR, 5RS) -5-PENETHYL-PYRROLIDIN-2-IL] -MEthyl] -PHENOL; (1RS, 5SR, 7aRS) -4- (5-PENETHYL-TETRAHYDRO-PYRROLO [1,2-c] OXAZOL-1-IL) PHENOL, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE COMPOUNDS ARE SELECTIVE BLOCKERS OF NMDA RECEPTORS (METHYL-D-ASPARATE), WHICH MODULATE NEURONAL ACTIVITY AND PLASTICITY AND MAY BE USEFUL FOR THE TREATMENT OF NEURODEGENERATION CAUSED BY RECEREBRAL ATTACK OR TRAUMA, FORMS OF CRONIC INFLUENCE OF NEURONAL ACTIVITY , PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, SCHIZOPHRENIA, ANXIETY AND DEPRESSION |